GLP-1 · PEPTIDE BLEND
What is CagriSema?
Medically reviewed by the G1 Peptides clinical team · Updated October 1, 2026
THE SHORT ANSWER
CagriSema is an investigational once-weekly injection that combines cagrilintide, an amylin analog, with semaglutide, a GLP-1 receptor agonist. It is being studied for obesity and type 2 diabetes.
CagriSema at a glance
- Type
- Peptide blend
- Also known as
- Cagrilintide + semaglutide
- Mechanism
- Cagrilintide (amylin) + semaglutide (GLP-1)
- Status
- Phase 3
- Half-life
- ~7 days
- Route
- Subcutaneous
- Dosing range in the literature
- 0.25–2.4 mg of each, weekly
- Onset
- 1–4 weeks for appetite reduction
- Storage
- Refrigerated (2–8 °C); use within the pharmacy beyond-use date
How CagriSema works
The two components act on separate satiety pathways. Semaglutide works through the GLP-1 receptor and cagrilintide through amylin receptors, with the aim of more weight loss than either produces alone.
What CagriSema is studied for
- Weight management
- Appetite control
- Type 2 diabetes
In phase 3 trials, adults with obesity lost roughly 20 to 23% of body weight on average over 68 weeks.
Being studied for something is not proof that it works. Results in individuals vary.
CagriSema dosing
Published protocols describe 0.25–2.4 mg of each, weekly, once weekly, given subcutaneous. Onset is typically reported at 1–4 weeks for appetite reduction.
These figures are context from the literature, not instructions. A licensed provider sets the dose and schedule for each patient.
CagriSema side effects and risks
- Nausea
- Vomiting
- Diarrhea
- Constipation
Tell your provider about every medication and condition before starting, and report anything unexpected. See peptide side effects and safety and who should not use peptides.
Is CagriSema FDA approved?
A late-stage investigational combination at the time of review. Approval status in this class is changing quickly; check the FDA for the current position.
Approval and trial status change. This page was last reviewed on October 1, 2026.
CagriSema at G1 Peptides
G1 Peptides does not currently supply CagriSema. A provider can discuss alternatives in a free consultation.
CagriSema questions
- What is CagriSema?
- CagriSema is an investigational once-weekly injection that combines cagrilintide, an amylin analog, with semaglutide, a GLP-1 receptor agonist. It is being studied for obesity and type 2 diabetes.
- What is CagriSema used for?
- CagriSema is studied for weight management, appetite control, and type 2 diabetes. In phase 3 trials, adults with obesity lost roughly 20 to 23% of body weight on average over 68 weeks.
- How does CagriSema work?
- The two components act on separate satiety pathways. Semaglutide works through the GLP-1 receptor and cagrilintide through amylin receptors, with the aim of more weight loss than either produces alone.
- Is CagriSema FDA approved?
- A late-stage investigational combination at the time of review. Approval status in this class is changing quickly; check the FDA for the current position.
- What is the typical CagriSema dosage?
- Published protocols describe 0.25–2.4 mg of each, weekly, given subcutaneous. This is context from the literature, not a recommendation: a licensed provider sets the dose.
- What are the side effects of CagriSema?
- Risks noted for CagriSema include nausea, vomiting, diarrhea, and constipation. Tell your provider about your medications and conditions before starting.
- How long do the peptides in CagriSema last in the body?
- The reported half-life is ~7 days. Onset is typically reported at 1–4 weeks for appetite reduction.
- How should CagriSema be stored?
- Refrigerated (2–8 °C); use within the pharmacy beyond-use date.
For educational purposes only, and not medical advice. These statements have not been evaluated by the FDA. Nothing on this page is intended to diagnose, treat, cure, or prevent any disease. Use any compound only under the guidance of a licensed provider.